-
Something wrong with this record ?
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
JC. Fruchart, RD. Santos, C. Aguilar-Salinas, M. Aikawa, K. Al Rasadi, P. Amarenco, PJ. Barter, R. Ceska, A. Corsini, JP. Després, P. Duriez, RH. Eckel, MV. Ezhov, M. Farnier, HN. Ginsberg, MP. Hermans, S. Ishibashi, F. Karpe, T. Kodama, W....
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
BioMedCentral
from 2002-12-01
BioMedCentral Open Access
from 2002
Directory of Open Access Journals
from 2002
Free Medical Journals
from 2002
PubMed Central
from 2002
Europe PubMed Central
from 2002
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2002-01-01
Open Access Digital Library
from 2002-04-01
Open Access Digital Library
from 2002-01-01
Medline Complete (EBSCOhost)
from 2002-04-08
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2002
Springer Nature OA/Free Journals
from 2002-12-01
- MeSH
- Benzoxazoles adverse effects therapeutic use MeSH
- Patient Safety MeSH
- Biomarkers blood MeSH
- Butyrates adverse effects therapeutic use MeSH
- Molecular Targeted Therapy MeSH
- Dyslipidemias blood diagnosis drug therapy MeSH
- Risk Assessment MeSH
- Hypolipidemic Agents adverse effects therapeutic use MeSH
- Cardiovascular Diseases blood diagnosis prevention & control MeSH
- Consensus MeSH
- Humans MeSH
- Lipids blood MeSH
- PPAR alpha agonists metabolism MeSH
- Risk Factors MeSH
- Signal Transduction MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
Cardiovascular Medicine Brigham and Women's Hospital Harvard Medical School Boston MA USA
Columbia University Vagelos College of Physicians and Surgeons New York USA
Department of Cardiology Faculty of Medicine Hacettepe University Ankara Turkey
Department of Clinical Biochemistry Rigshospitalet
Department of Clinical Biochemistry Sultan Qaboos University Hospital Muscat Oman
Department of Endocrinology Diabetology Jaslok Hospital and Research Centre Mumbai India
Department of Internal Medicine Faculty of Medicine University of Tsukuba Ibaraki 305 8575 Japan
Department of Medicine and Theraputics The Chinese University of Hong Kong Hong Kong Hong Kong
Department of Medicine DIMED University of Padua Padua Italy
Department of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
Department of Neurology and Stroke Center Paris Diderot Sorbonne University Paris France
Department of Pharmacological and Biomolecular Sciences Università Degli Studi di Milano Milan Italy
Deutsches Herzzentrum München Technische Universitat München Germany
Faculté de Pharmacie de Lille Lille France
Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK
Laboratory of Lipid Disorders National Cardiology Research Center Moscow Russian Federation
Lipid Clinic Point Médical and Department of Cardiology CHU Dijon Bourgogne Dijon France
Lipid Research Group School of Medical Sciences University of New South Wales Sydney NSW Australia
National Cerebral and Cardiovascular Center Suita Osaka Japan
R3i Foundation Picassoplatz 8 4010 Basel Switzerland
Ruddy Canadian Cardiovascular Genetics Centre University of Ottawa Heart Institute Ottawa Canada
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006286
- 003
- CZ-PrNML
- 005
- 20200525100928.0
- 007
- ta
- 008
- 200511s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12933-019-0864-7 $2 doi
- 035 __
- $a (PubMed)31164165
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Fruchart, Jean-Charles $u R3i Foundation, Picassoplatz 8, 4010, Basel, Switzerland. jean-Charles.fruchart@r3i.org.
- 245 14
- $a The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation / $c JC. Fruchart, RD. Santos, C. Aguilar-Salinas, M. Aikawa, K. Al Rasadi, P. Amarenco, PJ. Barter, R. Ceska, A. Corsini, JP. Després, P. Duriez, RH. Eckel, MV. Ezhov, M. Farnier, HN. Ginsberg, MP. Hermans, S. Ishibashi, F. Karpe, T. Kodama, W. Koenig, M. Krempf, S. Lim, AJ. Lorenzatti, R. McPherson, JM. Nuñez-Cortes, BG. Nordestgaard, H. Ogawa, CJ. Packard, J. Plutzky, CI. Ponte-Negretti, A. Pradhan, KK. Ray, Ž. Reiner, PM. Ridker, M. Ruscica, S. Sadikot, H. Shimano, P. Sritara, JK. Stock, TC. Su, AV. Susekov, A. Tartar, MR. Taskinen, A. Tenenbaum, LS. Tokgözoğlu, B. Tomlinson, A. Tybjærg-Hansen, P. Valensi, M. Vrablík, W. Wahli, GF. Watts, S. Yamashita, K. Yokote, A. Zambon, P. Libby,
- 520 9_
- $a In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a benzoxazoly $x škodlivé účinky $x terapeutické užití $7 D001583
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a butyráty $x škodlivé účinky $x terapeutické užití $7 D002087
- 650 _2
- $a kardiovaskulární nemoci $x krev $x diagnóza $x prevence a kontrola $7 D002318
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a dyslipidemie $x krev $x diagnóza $x farmakoterapie $7 D050171
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypolipidemika $x škodlivé účinky $x terapeutické užití $7 D000960
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a PPAR alfa $x agonisté $x metabolismus $7 D047493
- 650 _2
- $a bezpečnost pacientů $7 D061214
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Santos, Raul D $u Hospital Israelita Albert Einstein, and Lipid Clinic, Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.
- 700 1_
- $a Aguilar-Salinas, Carlos $u Unidad de Investigacion de Enfermedades Metabolicas, Department of Endocrinolgy and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico.
- 700 1_
- $a Aikawa, Masanori $u Center for Interdisciplinary Cardiovascular Sciences and Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine and Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Al Rasadi, Khalid $u Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman.
- 700 1_
- $a Amarenco, Pierre $u Department of Neurology and Stroke Center, Paris-Diderot-Sorbonne University, Paris, France.
- 700 1_
- $a Barter, Philip J $u Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
- 700 1_
- $a Ceska, Richard $u IIIrd Dept Int. Med, Center for Preventive Cardiology, 3rd Internal Medicine Clinic, University General Hospital and Charles University, Prague, Czech Republic.
- 700 1_
- $a Corsini, Alberto $u Department of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, Milan, Italy.
- 700 1_
- $a Després, Jean-Pierre $u Centre de recherche sur les soins et les services de première ligne-Université Laval du CIUSSS de la Capitale-Nationale, Department of Kinesiology, Faculty of Medicine, Université Laval, Québec, QC, Canada.
- 700 1_
- $a Duriez, Patrick $u INSERM, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, University of Lille, Faculty of Pharmacy, University of Lille, UDSL, Lille, France.
- 700 1_
- $a Eckel, Robert H $u Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA.
- 700 1_
- $a Ezhov, Marat V $u Laboratory of Lipid Disorders, National Cardiology Research Center, Moscow, Russian Federation.
- 700 1_
- $a Farnier, Michel $u Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.
- 700 1_
- $a Ginsberg, Henry N $u Columbia University Vagelos College of Physicians and Surgeons, New York, USA.
- 700 1_
- $a Hermans, Michel P $u Division of Endocrinology and Nutrition, Cliniques Universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium.
- 700 1_
- $a Ishibashi, Shun $u Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Japan.
- 700 1_
- $a Karpe, Fredrik $u OCDEM, University of Oxford and the NIHR Oxford Biomedical Research Centre, OUH Foundation Trust, Churchill Hospital, Oxford, UK.
- 700 1_
- $a Kodama, Tatsuhiko $u Laboratory for System Biology and Medicine Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
- 700 1_
- $a Koenig, Wolfgang $u Deutsches Herzzentrum München, Technische Universitat München, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
- 700 1_
- $a Krempf, Michel $u Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France. Inra, UMR 1280, Physiologie des Adaptations Nutritionnelles, Nantes, France. Department of Endocrinology, Metabolic diseases and Nutrition, G and R Laennec Hospital, Nantes, France.
- 700 1_
- $a Lim, Soo $u Department of Internal Medicine, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Seongnam, Republic of Korea.
- 700 1_
- $a Lorenzatti, Alberto J $u DAMIC Medical Institute/Rusculleda Foundation for Research, Córdoba, Argentina. Cardiology Department, Córdoba Hospital, Córdoba, Argentina.
- 700 1_
- $a McPherson, Ruth $u Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Canada.
- 700 1_
- $a Nuñez-Cortes, Jesus Millan $u Internal Medicine, Lipids Unit, Gregorio Marañón University Hospital, Madrid, Spain. Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. Instituto de Investigaciones Sanitarias Gregorio Marañón, Madrid, Spain.
- 700 1_
- $a Nordestgaard, Børge G $u Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Ogawa, Hisao $u National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
- 700 1_
- $a Packard, Chris J $u Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
- 700 1_
- $a Plutzky, Jorge $u Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Ponte-Negretti, Carlos I $u Unidad de Prevención Cardiometabólica Cardiocob. Servicio de Cardiología Hospital el Pino Santiago de Chile, Sociedad Inter Americana de Cardiología SIAC Chairman Cardiovascular Prevention Comite, Santiago de Chile, Chile.
- 700 1_
- $a Pradhan, Aruna $u Division of Cardiovascular Medicine, VA Boston Medical Center, Boston, MA, USA. Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Ray, Kausik K $u Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK.
- 700 1_
- $a Reiner, Željko $u Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, Zagreb University, Kispaticeva 12, Zagreb, Croatia.
- 700 1_
- $a Ridker, Paul M $u Division of Cardiovascular Medicine and Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Ruscica, Massimiliano $u Department of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, Milan, Italy.
- 700 1_
- $a Sadikot, Shaukat $u Department of Endocrinology/Diabetology, Jaslok Hospital and Research Centre, Mumbai, India.
- 700 1_
- $a Shimano, Hitoshi $u Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki, 305-8575, Japan.
- 700 1_
- $a Sritara, Piyamitr $u Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- 700 1_
- $a Stock, Jane K $u R3i Foundation, Picassoplatz 8, 4010, Basel, Switzerland.
- 700 1_
- $a Su, Ta-Chen $u Departments of Internal Medicine and Environmental and Occupational Medicine, National Taiwan University; Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan.
- 700 1_
- $a Susekov, Andrey V $u Faculty of Clinical Pharmacology and Therapeutics, Academy for Postgraduate Continuous Medical Education, Moscow, Russian Federation.
- 700 1_
- $a Tartar, André $u Faculté de Pharmacie de Lille, Lille, France.
- 700 1_
- $a Taskinen, Marja-Riitta $u Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki and Clinical Research Institute, HUCH Ltd., Helsinki, Finland.
- 700 1_
- $a Tenenbaum, Alexander $u Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. Cardiac Rehabilitation Institute, Sheba Medical Center, 5265601, Tel Hashomer, Israel.
- 700 1_
- $a Tokgözoğlu, Lale S $u Department of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
- 700 1_
- $a Tomlinson, Brian $u Department of Medicine & Theraputics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
- 700 1_
- $a Tybjærg-Hansen, Anne $u Department of Clinical Biochemistry, Rigshospitalet; Copenhagen University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. The Copenhagen General Population Study, Herlev and Gentofte Hospital, Herlev, Denmark.
- 700 1_
- $a Valensi, Paul $u Department of Endocrinology, Diabetology and Nutrition, Jean-Verdier Hospital (AP-HP), Paris 13 University, Sorbonne Paris Cité, CRNH-IdF, CINFO, 93140, Bondy, France.
- 700 1_
- $a Vrablík, Michal $u 3rd Department of Medicine, 1st Faculty of Medicine of Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Wahli, Walter $u Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Clinical Sciences Building, 11 Mandalay Road, Singapore, 308232, Singapore. Center for Integrative Genomics, Université de Lausanne, Le Génopode, CH-1015, Lausanne, Switzerland. Institut National de La Recherche Agronomique (INRA), UMR1331 ToxAlim, Toulouse, France.
- 700 1_
- $a Watts, Gerald F $u Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, School of Medicine, University of Western Australia, Perth, Australia.
- 700 1_
- $a Yamashita, Shizuya $u Rinku General Medical Center, Izumisano, Osaka, Japan. Department of Community Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
- 700 1_
- $a Yokote, Koutaro $u Department of Endocrinology, Hematology and Gerontology, Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
- 700 1_
- $a Zambon, Alberto $u Department of Medicine-DIMED, University of Padua, Padua, Italy.
- 700 1_
- $a Libby, Peter $u Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- 773 0_
- $w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 18, č. 1 (2019), s. 71
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31164165 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200525100928 $b ABA008
- 999 __
- $a ok $b bmc $g 1525144 $s 1096342
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 18 $c 1 $d 71 $e 20190604 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
- LZP __
- $a Pubmed-20200511
